Amelia M Jernigan1, Haider Mahdi, Peter G Rose. 1. Section of Gynecologic Oncology, Women's Health Institute and Gynecology and Obstetrics, The Cleveland Clinic, Cleveland OH.
Abstract
OBJECTIVES: To estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival. METHODS AND MATERIALS: A total of 1240 cases of EOC treated between 1995 and 2014 were reviewed to identify CNS metastasis. Demographics, treatment, family history, genetic testing, and survival outcomes were recorded. Women were then classified as HBOC+ or HBOC- based on histories and genetic testing results. Kaplan-Meier survival curves and univariable Cox proportional hazards models were used. RESULTS: Of 1240 cases, 32 cases of EOC with CNS metastasis were identified (2.58%). Median age was 52.13 (95% confidence interval [CI], 40.56-78.38) years, and 87.10% had stage III to IV disease. Among those with documented personal and family history, 66.7% (20/30) were suspicious for HBOC syndrome. Among those who underwent germline testing, 71.43% (5/7) had a pathogenic BRCA mutation. The median time from diagnosis to CNS metastasis was 29.17 (95% CI, 0-187.91) months. At a median survival of 5.97 (95% CI, 0.20-116.95) months from the time of CNS metastasis and 43.76 (95% CI, 1.54-188.44) months from the time of EOC diagnosis, 29 women died of disease. Univariate Cox proportional hazard models were used to compare HBOC- to HBOC+ women and did not reveal a significant difference for survival outcomes. CONCLUSIONS: Confirmed BRCA mutations and histories concerning for HBOC syndrome are common in women with EOC metastatic to the CNS. We did not demonstrate a relationship between HBOC status and survival outcomes, but were not powered to do so.
OBJECTIVES: To estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival. METHODS AND MATERIALS: A total of 1240 cases of EOC treated between 1995 and 2014 were reviewed to identify CNS metastasis. Demographics, treatment, family history, genetic testing, and survival outcomes were recorded. Women were then classified as HBOC+ or HBOC- based on histories and genetic testing results. Kaplan-Meier survival curves and univariable Cox proportional hazards models were used. RESULTS: Of 1240 cases, 32 cases of EOC with CNS metastasis were identified (2.58%). Median age was 52.13 (95% confidence interval [CI], 40.56-78.38) years, and 87.10% had stage III to IV disease. Among those with documented personal and family history, 66.7% (20/30) were suspicious for HBOC syndrome. Among those who underwent germline testing, 71.43% (5/7) had a pathogenic BRCA mutation. The median time from diagnosis to CNS metastasis was 29.17 (95% CI, 0-187.91) months. At a median survival of 5.97 (95% CI, 0.20-116.95) months from the time of CNS metastasis and 43.76 (95% CI, 1.54-188.44) months from the time of EOC diagnosis, 29 womendied of disease. Univariate Cox proportional hazard models were used to compare HBOC- to HBOC+ women and did not reveal a significant difference for survival outcomes. CONCLUSIONS: Confirmed BRCA mutations and histories concerning for HBOC syndrome are common in women with EOC metastatic to the CNS. We did not demonstrate a relationship between HBOC status and survival outcomes, but were not powered to do so.
Authors: Marina Stasenko; Paulina Cybulska; Noah Feit; Vicky Makker; Jason Konner; Roisin E O'Cearbhaill; Kaled M Alektiar; Kathryn Beal; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Dennis S Chi; Oliver Zivanovic; Mario M Leitao; Karen A Cadoo; William P Tew Journal: Gynecol Oncol Date: 2019-05-18 Impact factor: 5.482
Authors: Alexandre André Balieiro Anastácio da Costa; Elizabeth Santana Dos Santos; Deborah Porto Cotrim; Natasha Carvalho Pandolfi; Marcelle Goldner Cesca; Henrique Mantoan; Solange Moraes Sanches; Adriana Regina Gonçalves Ribeiro; Louise de Brot; Graziele Bonvolim; Paulo Issamu Sanematsu; Ronaldo Pereira de Souza; Joyce Maria Lisboa Maya; Fabrício de Souza Castro; João Paulo da Nogueira Silveira Lima; Michael Jenwel Chen; Andrea Paiva Gadelha Guimarães; Glauco Baiocchi Journal: BMC Cancer Date: 2019-12-05 Impact factor: 4.430
Authors: Flavia Morales Vázquez; Horacio Noé López Basave; María Del Carmen Méndez Herrera; Ricardo Raziel Peña González Journal: Am J Case Rep Date: 2020-11-23